NYSE:PVCT

Provectus Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy PVCT

*Your capital is at risk

$0.0651

-0.0029 (-4.34%)

At Close: Jul 13, 2026

Provectus Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.39M and sold 0 PVCT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	1.39M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 30, 2026 Buy	Series D-1 Convertible Preferred Stock A-Award	Pershing Edward CEO	CEO / President	45 860 Value: $3K
Jun 30, 2026 Buy	Series D-1 Convertible Preferred Stock A-Award	Bailey Webster Director	Director	48 917 Value: $3K
Jun 30, 2026 Buy	Series D-1 Convertible Preferred Stock A-Award	Lacey John Iii Director	Director	48 917 Value: $3K
Jun 30, 2026 Buy	Series D-1 Convertible Preferred Stock A-Award	Rodrigues Dominic President	CEO / President	45 860 Value: $3K
Jun 05, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	9 436 Value: $594
Jun 05, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
May 28, 2026 Buy	8% Unsecured Convertible Promissory Note A-Award	Pershing Edward CEO	CEO / President	0 Value: $0
May 23, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	32 089 Value: $2K
May 23, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
May 15, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
May 15, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	22 651 Value: $2K
May 07, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	18 876 Value: $1K
May 07, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
Apr 29, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
Apr 29, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	30 202 Value: $2K
Apr 04, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	33 977 Value: $2K
Apr 04, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
Mar 25, 2026 Buy	8% Unsecured Convertible Promissory Note A-Award	Pershing Edward CEO	CEO / President	0 Value: $0
Mar 20, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
Mar 20, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	49 067 Value: $2K
Mar 12, 2026 Buy	8% Unsecured Convertible Promissory Note A-Award	Pershing Edward CEO	CEO / President	0 Value: $0
Mar 05, 2026 Buy	8% Unsecured Convertible Promissory Note A-Award	Pershing Edward CEO	CEO / President	0 Value: $0
Feb 26, 2026 Buy	8% Unsecured Convertible Promissory Note A-Award	Pershing Edward CEO	CEO / President	0 Value: $0
Feb 20, 2026 Buy	8% Unsecured Convertible Promissory Note M-Exempt	Pershing Edward CEO	CEO / President	0 Value: $0
Feb 20, 2026 Buy	Series D-1 Convertible Preferred Stock M-Exempt	Pershing Edward CEO	CEO / President	47 180 Value: $2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROVECTUS PHARMACEUTICALS, INC

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastati...

Read Full Profile Here